Preclinical
The placenta, sometimes called afterbirth, is described as an organ that develops in the uterus during pregnancy. Although research has been conducted on placentas for decades, three important studies were recently published related to the science of the placenta.
There are plenty of great scientific research stories out this week. Here’s a look at just a few of them. Although most readers will already be aware of it, the biggest story, perhaps the biggest story of the year—certainly the most controversial—involves a Chinese researcher who used CRISPR to modify embryos to be resistant to HIV, and the recent birth of a set of twins.
Scientists from a consortium of prominent research institutions studied the entire genomes of more than 20,000 people with attention deficit/hyperactivity disorder (ADHD) and compared them to the genomes of 35,000 who did not have ADHD. They identified 12 genetic variants in the ADHD group, suggesting an increased risk of ADHD compared to those without the variants.
Roche subsidiary Genentech snaps up Jecure and its portfolio of preclinical NLRP3 inhibitors aimed at serious inflammatory diseases.
Shares of Boston-based Zafgen, Inc. plunged more than 32 percent in pre-market trading after the company announced the U.S. Food and Drug Administration has slapped a clinical hold on its plans to launch a clinical trial in the United States for an experimental diabetes medicine due to safety concerns.
Sareum Holdings plc has today reported new preclinical data that support its ongoing clinical trial with SRA737 as a monotherapy in ovarian cancer.
Shifa Biomedical Corporation today announced exciting preclinical data involving the company’s pre-clinical candidate, P-21, which interferes with the interaction between PCSK9 and the LDL receptor (LDLR).
Even with the Thanksgiving week, there is interesting and exciting research being conducted and published. Here’s a look.
Society for Neuroscience Features OTO-413 Presentation as Neuroscience 2018 Hot Topic
- Partner MD Anderson Cancer Center will present preclinical data on HDP-101 for effective 17p deletion in multiple myeloma in an oral presentation
PRESS RELEASES